Skip to main content
SpringerLink
Log in

Could anti-PD-1 be a therapeutic alternative for metastatic pleomorphic dermal sarcoma?

  • Correspondence
  • Published:
European Journal of Dermatology Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol 2014; 11: 187–202.

    Article  CAS  Google Scholar 

  2. Maki RG, Wathen JK, Patel SR, et al. Randomized Phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration Study 002. J Clin Oncol 2007; 25: 2755–63.

    Article  CAS  Google Scholar 

  3. Wisdom AJ, Mowery YM, Riedel RF, Kirsch DG. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. Cancer 2018; 124: 3819–29.

    Article  Google Scholar 

  4. Kakimoto T, Matsumine A, Kageyama S, et al. Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma. Oncol Lett 2019; 17: 3937–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 2017; 171: 95065.e28.

    Google Scholar 

  6. Pollack SM, He Q, Yearley JH, et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer 2017; 123: 3291–304.

    Article  CAS  Google Scholar 

  7. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multi-centre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017; 18: 1493–501.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, CIC 1413, CRCINA Inserm 1232, CHU Nantes, Nantes, France

    Barbara Bregeon, Amir Khammari & Brigitte Dreno

  2. Pathology Department, CHU of Bordeaux, Bordeaux, France

    Marie-Laure Jullie & Hugues Begueret

Authors
  1. Barbara Bregeon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie-Laure Jullie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hugues Begueret
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amir Khammari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Brigitte Dreno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brigitte Dreno.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bregeon, B., Jullie, ML., Begueret, H. et al. Could anti-PD-1 be a therapeutic alternative for metastatic pleomorphic dermal sarcoma?. Eur J Dermatol 29, 650–651 (2019). https://doi.org/10.1684/ejd.2019.3656

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2019.3656

Search

Navigation